Table 3.
Ultrasound-based malignancy risk stratification systems | Sensitivity(%) | Specificity(%) | PPV(%) | NPV(%) | AUC | p |
---|---|---|---|---|---|---|
ATA | 23.3 (13.4–36.0) | 87.7 (82.9–91.5) | 31.1 (20.4–44.3) | 82.7 (80.5–84.7) | 0.555 (0.498–0.611) | p = 0.062 |
AACE/ACE/AME | 98.4 (91.3–99.9) | 3.84 (1.9–7.0) | 19.6 (19.0–20.3) | 90.9 (56.6–98.7) | 0.511 (0.455–0.567) | p = 0.266 |
K-TIRADS | 30.3 (19.6–42.9) | 84.3 (79.3–88.5) | 32.7 (23.5–43.6) | 82.7 (80.2–85.0) | 0.573 (0.517–0.627) | p = 0.017a |
EU-TIRADS | 33.9 (22.3–47.0) | 84.0 (78.9–88.3) | 33.9 (24.7–44.5) | 84.0 (81.3–86.3) | 0.589 (0.533–0.644) | p = 0.006a |
ACR-TIRADS | 38.8 (27.1–51.5) | 80.2 (74.8–84.8) | 33.3 (25.4–42.4) | 83.7 (80.7–86.2) | 0.595 (0.540–0.648) | p = 0.004a |
C–TIRADS | 26.9 (16.8–39.1) | 95.4 (92.1–97.6) | 60.0 (43.2–74.7) | 83.6 (81.5–85.5) | 0.611 (0.556–0.664) | p < 0.001a |
Numbers in parentheses are 95% confidence intervals
aThere was no significant difference between the AUCs of the above four systems (p > 0.05)
Abbreviations: PPV positive predictive value; NPV negative predictive value; ATA 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer; AACE/ACE/AME American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinology Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules (2016 Update); EU-TIRADS European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults; K-TIRADS Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations; ACR-TIRADS American College of Radiology Thyroid Imaging Reporting and Data System; C-TIRADS 2020 Chinese Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules